These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36318524)

  • 21. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
    Hood SC; Moher D; Barber GG
    CMAJ; 1996 Oct; 155(8):1053-9. PubMed ID: 8873633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of cilostazol and other therapies for intermittent claudication.
    Dawson DL
    Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the cilostazol safety database.
    Pratt CM
    Am J Cardiol; 2001 Jun; 87(12A):28D-33D. PubMed ID: 11434897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of intermittent claudication: cilostazol.
    Collins P; Brittenden J
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of intermittent claudication with pentoxifylline and cilostazol.
    Tjon JA; Riemann LE
    Am J Health Syst Pharm; 2001 Mar; 58(6):485-93; quiz 494-6. PubMed ID: 11286146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Padma 28 for intermittent claudication.
    Morling JR; Maxwell H; Stewart M
    Cochrane Database Syst Rev; 2013 Jul; (7):CD007371. PubMed ID: 23861015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exercise for intermittent claudication.
    Lane R; Ellis B; Watson L; Leng GC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD000990. PubMed ID: 25037027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilostazol: a novel treatment option in intermittent claudication.
    Cariski AT
    Int J Clin Pract Suppl; 2001 Apr; (119):11-8. PubMed ID: 11355274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.
    de Albuquerque RM; Virgini-Magalhães CE; Lencastre Sicuro F; Bottino DA; Bouskela E
    Angiology; 2008; 59(5):549-58. PubMed ID: 18388031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.
    Girolami B; Bernardi E; Prins MH; Ten Cate JW; Hettiarachchi R; Prandoni P; Girolami A; Büller HR
    Arch Intern Med; 1999 Feb; 159(4):337-45. PubMed ID: 10030306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.